Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile ...

Sanofi extended the deal again last year to cover another STAT6 degrader, and, two months ago, the French pharma paid out $15 million for the rights to a once-undruggable transcription factor.

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from ...

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International ConferenceKT-621, a potent, selective, oral STAT6 ...

Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family involved in the regulation of immune response and inflammation. The development of SH2 domain inhibitors ...

In the study, STAT6 levels were elevated in the lungs of a mouse model of intermittent hypoxia-induced PH. Deleting the protein eased disease severity in the mice and reduced signaling of an immune ...

NAB2-STAT6 FLAG becomes significantly localized to these peaks which have significant increases in EGR1 and ATAC-seq signal. (b) Motif analysis of 1394 NAB2-STAT6 FLAG peaks using HOMER shows EGR1, ...